Disaccharidase Activity Panel
Test in Focus
Mayo Clinic Labs’ new disaccharidase activity panel measures levels of five naturally occurring digestive enzymes to detect deficiencies that affect carbohydrate absorption. The panel, as explained by Mayo Clinic pediatric gastroenterologist Pua Hopson, D.O., in this episode of the "Answers From the Lab" podcast, is the gold standard for diagnosing disaccharidase deficiencies, which can cause chronic conditions like celiac disease.
“Oftentimes when we see these patients who have had chronic illness and have chronic symptoms going on for such a long time, it’s hard to piece together the history,” says Dr. Hopson. “It can be quite complex to tease out ‘A causes B.’ In doing an endoscopy the addition of this test may be really beneficial if you find a deficiency, and sometimes can provide a lot of clarity for your patients’ symptoms.”
Dr. Hopson explains that in the proper clinical setting, disaccharidase activity testing can increase disaccharidase disorder identification by 10% to 20%. “In these cases, you’ll have a higher chance of detecting abnormalities and overall helping your patients clinically.”
Listen to learn more about how disaccharidase activity testing improves patient outcomes by equipping providers with specific details about patients’ malabsorption disorders to confirm diagnosis and inform treatment choices.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluation of patients who present with signs or symptoms suggestive of disaccharidase disorders. This test is not intended for carrier detection.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.